title: Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer.
abstract: Most patients with advanced breast cancer develop osteolytic bone metastases, which have numerous complications. Because current therapies are not curative, new treatments are needed. Conditionally replicating adenoviruses (CRAds) are anticancer agents designed to infect and lyse tumor cells. However, in spite of their promise as selective cancer therapeutics, replicating adenoviruses have shown limited efficacy in the clinical setting. We hypothesized that a CRAd armed with osteoprotegerin (OPG) would eradicate bone metastases of breast cancer both directly, by oncolysis, and indirectly, by inhibiting osteoclastic bone resorption, and thus reducing the tumor burden. We constructed an armed CRAd (Ad5-Δ24-sOPG-Fc-RGD) by replacing viral E3B genes with a fusion of the ligand-binding domains of OPG and the Fc portion of human IgG1. Conditional replication was conferred by a 24-base pair deletion within E1A (Δ24), which prevents the binding of E1A to the retinoblastoma tumor suppressor/cell cycle regulator protein and limits replication in normal cells. Enhanced infection of cells expressing low levels of the primary Ad5 receptor was conferred by incorporating an arginine-glycine-aspartic acid (RGD) peptide sequence into the fiber knob to mediate binding to α(v) integrins. After characterization of the armed CRAd, we demonstrated that infection of breast cancer cells by Ad5-Δ24-sOPG-Fc-RGD both killed the infected cells by oncolysis and inhibited the formation of osteoclasts in an in vitro co-culture model. In a murine model of osteolytic bone metastases of breast cancer, the CRAd armed with shortened OPG (sOPG)-Fc reduced tumor burden in the bone and inhibited osteoclast formation more effectively than an unarmed CRAd.
authors.affiliation: Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Cody
authors.forename: A A
authors.initials: AA
authors.lastname: Rivera
authors.forename: G R
authors.initials: GR
authors.lastname: Lyons
authors.forename: S W
authors.initials: SW
authors.lastname: Yang
authors.forename: M
authors.initials: M
authors.lastname: Wang
authors.forename: D B
authors.initials: DB
authors.lastname: Sarver
authors.forename: D
authors.initials: D
authors.lastname: Wang
authors.forename: K S
authors.initials: KS
authors.lastname: Selander
authors.forename: H-C
authors.initials: HC
authors.lastname: Kuo
authors.forename: S
authors.initials: S
authors.lastname: Meleth
authors.forename: X
authors.initials: X
authors.lastname: Feng
authors.forename: G P
authors.initials: GP
authors.lastname: Siegal
authors.forename: G P
authors.initials: GP
authors.lastname: Siegall
authors.forename: J T
authors.initials: JT
authors.lastname: Douglas
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology / Q000556:secondary*; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D051379:Mice; D053244:Osteoprotegerin / Q000235:genetics* / Q000378:metabolism; D047368:Tumor Burden / Q000235:genetics; D014779:Virus Replication
chemical_list: D002352:Carrier Proteins; D053244:Osteoprotegerin; C029702:prolactin-binding protein
references.citation: J Biol Chem. 1998 Jun 5;273(23):14363-7
references.pmid: 9603945
references.citation: Cancer Res. 2005 Sep 1;65(17):7682-90
references.pmid: 16140935
references.citation: Virology. 2004 Mar 1;320(1):121-34
references.pmid: 15003868
references.citation: Cancer Res. 2005 Nov 15;65(22):10154-8
references.pmid: 16287998
references.citation: J Clin Invest. 2000 May;105(9):1169-72
references.pmid: 10791988
references.citation: Nat Rev Cancer. 2002 Aug;2(8):584-93
references.pmid: 12154351
references.citation: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474
references.pmid: 16034900
references.citation: Proc Natl Acad Sci U S A. 2008 Apr 8;105(14):5483-8
references.pmid: 18391209
references.citation: J Virol. 1996 Nov;70(11):7498-509
references.pmid: 8892868
references.citation: Bone. 2007 Feb;40(2):471-8
references.pmid: 17092788
references.citation: Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1943-8
references.pmid: 12576544
references.citation: Cell. 1997 Apr 18;89(2):309-19
references.pmid: 9108485
references.citation: Cancer. 2003 Feb 1;97(3 Suppl):887-92
references.pmid: 12548591
references.citation: Cancer Res. 2002 Feb 15;62(4):1063-8
references.pmid: 11861383
references.citation: Clin Cancer Res. 2002 Nov;8(11):3348-59
references.pmid: 12429621
references.citation: Cancer Res. 2003 Jan 15;63(2):287-9
references.pmid: 12543775
references.citation: Oncogene. 2000 Jan 6;19(1):2-12
references.pmid: 10644974
references.citation: Cell Tissue Res. 2002 Mar;307(3):337-45
references.pmid: 11904770
references.citation: Cancer. 2003 Feb 1;97(3 Suppl):834-9
references.pmid: 12548583
references.citation: Oncologist. 2000;5(6):463-70
references.pmid: 11110597
references.citation: Clin Exp Metastasis. 2007;24(5):389-401
references.pmid: 17541709
references.citation: Nat Biotechnol. 2000 Jul;18(7):723-7
references.pmid: 10888838
references.citation: J Clin Invest. 2001 May;107(10):1235-44
references.pmid: 11375413
references.citation: Mol Ther. 2000 May;1(5 Pt 1):391-405
references.pmid: 10933960
references.citation: Clin Exp Metastasis. 2003;20(4):327-34
references.pmid: 12856720
references.citation: J Bone Miner Res. 2000 Jul;15(7):1337-45
references.pmid: 10893682
references.citation: Clin Exp Metastasis. 2004;21(2):119-28
references.pmid: 15168729
references.citation: Cancer Metastasis Rev. 1989 Aug;8(2):98-101
references.pmid: 2673568
references.citation: J Virol. 1996 Apr;70(4):2296-306
references.pmid: 8642656
references.citation: Cancer Res. 2001 Jun 1;61(11):4432-6
references.pmid: 11389072
references.citation: J Bone Miner Res. 1987 Dec;2(6):595-610
references.pmid: 3455637
references.citation: Clin Exp Metastasis. 2004;21(6):543-52
references.pmid: 15679052
references.citation: Cell. 2008 Feb 8;132(3):397-409
references.pmid: 18267072
references.citation: Clin Cancer Res. 2001 Jun;7(6):1654-60
references.pmid: 11410503
references.citation: Nat Med. 2000 Oct;6(10):1134-9
references.pmid: 11017145
references.citation: Endocr Rev. 1998 Feb;19(1):18-54
references.pmid: 9494779
references.citation: Endocrinology. 1999 Oct;140(10):4451-8
references.pmid: 10499498
references.citation: Clin Exp Metastasis. 2006;23(1):19-31
references.pmid: 16715352
references.citation: J Virol. 1998 Dec;72(12):9706-13
references.pmid: 9811704
references.citation: Gynecol Oncol. 2007 Apr;105(1):113-21
references.pmid: 17173958
references.citation: Endocrinology. 2000 Sep;141(9):3478-84
references.pmid: 10965921
references.citation: Clin Exp Metastasis. 2008;25(2):119-29
references.pmid: 18064531
references.citation: Clin Cancer Res. 2001 Jan;7(1):120-6
references.pmid: 11205899
references.citation: Mol Cancer Ther. 2008 Jul;7(7):2160-9
references.pmid: 18606716
references.citation: Gene Ther. 2001 Aug;8(15):1142-8
references.pmid: 11509944
references.citation: Endocrinology. 1989 Oct;125(4):1805-13
references.pmid: 2676473
references.citation: Cancer Res. 2004 May 15;64(10):3479-85
references.pmid: 15150101
references.citation: Gene Ther. 2001 Jan;8(2):89-98
references.pmid: 11313778
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8697-703
references.pmid: 15623655
references.citation: J Natl Cancer Inst. 2006 Feb 1;98(3):203-14
references.pmid: 16449680
references.citation: J Clin Invest. 1996 Oct 1;98(7):1544-9
references.pmid: 8833902
references.citation: Cancer Gene Ther. 2009 Jun;16(6):473-88
references.pmid: 19197323
references.citation: Cancer Res. 2003 Mar 1;63(5):912-6
references.pmid: 12615702
references.citation: Endocr Rev. 1999 Jun;20(3):345-57
references.pmid: 10368775
references.citation: Prostate. 2002 Jun 1;52(1):20-33
references.pmid: 11992617